Trial
NCT03585101
A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
Phase IVWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
University of California, Los Angeles
Collaborators
Merck Sharp & Dohme LLC
Condition
Hepatitis C
Intervention
Elbasvir/grazoprevir
Why stopped
Funding no longer available
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-08-07